News and Announcements
Novapep’s Pioneering Approach to Treating Inflammatory Bowel Diseases
- Published October 15, 2024 7:42AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join Jay Hennock, CEO of Novapep, as he unveils the company’s mission to address unmet medical needs through peptide-based therapies.
Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a US$20 billion market) and superior to corticosteroids, but with minimal expected side effects.
This video provides a compelling overview of their research and development efforts, focusing on inflammatory skin disorders, bowel disease, and sepsis, and their impact on global health.
Executive Interviews
Why Are Fewer Companies Going Public in Australia?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
From Trash to Treasure: Inside Australia’s First Commercial Waste-to-Hydrogen Facility
Greenhill Energy’s pioneering waste-to-hydrogen facility marks a significant step in sustainable energy. This Australian innovation is transforming waste management into clean, valuable hydrogen, presenting investors with a unique, forward-thinking opportunity.
Backed By Leading Investment Groups and Family Offices
